[HTML][HTML] Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery
T Ren, Y Mi, J Wei, X Han, X Zhang, Q Zhu, T Yue… - Molecules, 2024 - mdpi.com
Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
[HTML][HTML] Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery
T Ren, Y Mi, J Wei, X Han, X Zhang, Q Zhu, T Yue… - Molecules, 2024 - ncbi.nlm.nih.gov
Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.
T Ren, Y Mi, J Wei, X Han, X Zhang, Q Zhu… - …, 2024 - search.ebscohost.com
Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.
T Ren, Y Mi, J Wei, X Han, X Zhang, Q Zhu… - Molecules (Basel …, 2024 - europepmc.org
Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery
T Ren, Y Mi, J Wei, X Han, X Zhang… - Molecules (Basel …, 2024 - pubmed.ncbi.nlm.nih.gov
Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …